Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 11,800 shares, an increase of 110.7% from the December 31st total of 5,600 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 102,700 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. MAI Capital Management purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned about 51.66% of Kazia Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Price Performance

NASDAQ KZIA traded down $0.39 during trading on Friday, hitting $1.52. 1,735,239 shares of the company traded hands, compared to its average volume of 5,365,462. The business has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $3.88. Kazia Therapeutics has a 12 month low of $1.32 and a 12 month high of $15.80.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.